Literature DB >> 17333202

Therapy of recurrent disease after radical prostatectomy in 2007.

Rudolf Schwarz1, Markus Graefen, Andreas Krüll.   

Abstract

Recurrence rates of 20-40% after prostatectomy are described. This review will discuss curative treatment options for salvage after primary therapy. Relevant information was identified through searches of published studies, abstracts from scientific meetings, and review articles. Clinical experience in salvage therapy is limited. Conformal radiotherapy to the prostatic bed for PSA relapse and biopsy proven local recurrences after prostatectomy remains the only potentially curative therapy. It can provide durable biochemical control in a range from 17 to 78%. Salvage radiotherapy is well tolerated. Some prognostic factors exist which can help to select the right patient for this treatment. Patients have to be treated early for PSA relapse. Conformal radiotherapy to the prostatic bed for PSA relapse and biopsy proven local recurrences after prostatectomy is a good documented curative therapy. In a patient with a high probability of local recurrence early radiotherapy for PSA relapse is suggested.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17333202     DOI: 10.1007/s00345-007-0147-x

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  44 in total

1.  Results of three dimensional conformal radiotherapy and hormonal therapy for local recurrence after radical prostatectomy.

Authors:  Rudolf Schwarz; Andreas Krüll; Silke Tribius; Winfried Alberti
Journal:  Strahlenther Onkol       Date:  2005-07       Impact factor: 3.621

2.  Salvage radiotherapy after radical prostatectomy for prostate adenocarcinoma: analysis of efficacy and prognostic factors.

Authors:  Ashish K Chawla; Harjot K Thakral; Anthony L Zietman; William U Shipley
Journal:  Urology       Date:  2002-05       Impact factor: 2.649

3.  Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy.

Authors:  J A Cadeddu; A W Partin; T L DeWeese; P C Walsh
Journal:  J Urol       Date:  1998-01       Impact factor: 7.450

4.  PSA based review of adjuvant and salvage radiation therapy vs. observation in postoperative prostate cancer patients.

Authors:  R E Peschel; T J Robnett; D Hesse; C R King; R D Ennis; P B Schiff; L D Wilson
Journal:  Int J Cancer       Date:  2000-02-20       Impact factor: 7.396

Review 5.  Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer.

Authors:  F A Vicini; E L Ziaja; L L Kestin; D S Brabbins; J S Stromberg; J A Gonzalez; A A Martinez
Journal:  Urology       Date:  1999-07       Impact factor: 2.649

6.  (IN)-efficacy of salvage radiotherapy for rising PSA or clinically isolated local recurrence after radical prostatectomy.

Authors:  Richard Choo; George Hruby; Julie Hong; Edward Bahk; Eugene Hong; Cyril Danjoux; Gerard Morton; Gerrit DeBoer
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-06-01       Impact factor: 7.038

7.  Salvage brachytherapy for local recurrence after radical prostatectomy and subsequent external beam radiotherapy.

Authors:  Andrea Losa; Luciano Dante Nava; Nadia Di Muzio; Paola Mangili; Barbara Longobardi; Patrizio Rigatti; Giorgio Guazzoni
Journal:  Urology       Date:  2003-12       Impact factor: 2.649

8.  Direct segment aperture and weight optimization for intensity-modulated radiotherapy of prostate cancer.

Authors:  Gert De Meerleer; Luc Vakaet; Werner De Gersem; Geert Villeirs; Wilfried De Neve
Journal:  Strahlenther Onkol       Date:  2004-03       Impact factor: 3.621

9.  Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer.

Authors:  S M Eulau; D J Tate; T A Stamey; M A Bagshaw; S L Hancock
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-07-01       Impact factor: 7.038

10.  Impact of radical prostatectomy in the management of clinically localized disease.

Authors:  D F Paulson
Journal:  J Urol       Date:  1994-11       Impact factor: 7.450

View more
  1 in total

1. 

Authors:  Jonathan I Izawa
Journal:  Can Urol Assoc J       Date:  2009-06       Impact factor: 1.862

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.